Table 6. Rates of ocular adverse effects of RCTs evaluating bevacizumab for indirect comparison and dose-relationship evaluation.

Study	Endophthalmitis (%)		Uveitis (%)		Retinal detachment (%)		Retinal tear (%)		Lens damage (traumatic) (%)		Vitreous haemorrhage (%)
	1.0 mg	PDT+T	1.0 mg	PDT+T	1.0 mg	PDT+T	1.0 mg	PDT+T	1.0 mg	PDT+T	1.0 mg	PDT+T
Sacu et al. 2009 [26]	0.0	0.0	0.0	0.7	1.5	0.0	0.0	0.7	0.0	0.0	1.5	0.0
	1.25 mg	PDT+B	1.25 mg	PDT+B	1.25 mg	PDT+B	1.25 mg	PDT+B	1.25 mg	PDT+B	1.25 mg	PDT+B
Costagliola et al. 2010 [27]	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
	1.25 mg	UC	1.25 mg	UC	1.25 mg	UC	1.25 mg	UC	1.25 mg	UC	1.25 mg	UC
ABC trial 2010 [28]	0.0	0.0	3.0	2.0	0.0	2.0	0.0	0.0	0.0	0.0	2.0	0.0

B: Bevacizumab. Nr: Not reported. T: Triamcinolone. UC: Usual care.